CytoSorbents (CTSO) Stock Forecast & Price Target

CytoSorbents Corp has demonstrated a solid financial performance, reflecting a fourth-quarter gross margin expansion to an expected range of 73% to 75% and an overall full-year gross margin improvement to approximately 72%. The company's revenue for the year increased by 4% to $37.1 million, and management anticipates continued improvements with gross margins projected between 71%-74% for FY26, coupled with a path toward operating cash flow breakeven in the second half of 2026. Additionally, strategic balance sheet actions and operational changes are expected to enhance profitability, with a focus on market stabilization in Germany and international diversification further supporting the company’s positive outlook.

CytoSorbents Corp experienced a decline in revenue from Germany by 10%, contributing to an overall flat revenue growth of approximately 4% for the full year, reaching around $37.0 million. The company is facing challenges with patient imbalances in the U.S. market and has opted to deliberately slow its regulatory submissions to align with the FDA, which suggests uncertainty in future growth timelines. Given these factors, CytoSorbents's stock is viewed as trading at a distressed valuation, indicating a negative outlook driven by underlying business challenges and regulatory delays.